Ovid Therapeutics (OVID) Assets (2016 - 2026)

Ovid Therapeutics' Assets history runs 11 years deep, the most recent figure standing at $225.6 million for Q1 2026.

• Quarterly Assets rose 176.32% year-over-year to $225.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $225.6 million (up 176.32% YoY) and the FY2025 annual result came in at $150.9 million, up 63.76% from the prior year.
• Assets was $225.6 million for Q1 2026 at Ovid Therapeutics, up from $150.9 million in the prior quarter.
• Across five years, Assets topped out at $225.6 million in Q1 2026 and bottomed at $63.8 million in Q3 2025.
• A 5-year average of $134.2 million and a median of $136.2 million in 2023 frame the typical range for Assets.
• Annual changes were most pronounced in 2025 — Assets sank 37.96% — and 2026, when it jumped 176.32%.
• Ovid Therapeutics' Assets stood at $155.3 million in 2022, then dropped by 7.24% to $144.0 million in 2023, then sank by 36.01% to $92.2 million in 2024, then soared by 63.76% to $150.9 million in 2025, then jumped by 49.49% to $225.6 million in 2026.
• Business Quant data shows OVID's Assets at $225.6 million in Q1 2026, $150.9 million in Q4 2025, and $63.8 million in Q3 2025.